Trialjectory, a startup that matches most cancers sufferers to medical trials, introduced Monday it had raised $20 million in Sequence A funding.
The spherical was led by Perception Companions, with participation from JAL Ventures, Contour Enterprise Companions, Rho Capital and TIA Ventures.
WHAT IT DOES
The corporate affords an AI-enabled platform the place sufferers can enter details about their sort of most cancers and situation and be matched to open medical trials.
Trialjectory additionally works with pharmaceutical corporations to assist them recruit sufferers, discover potential obstacles to entry and construct trials with various populations.
“Harnessing the ability of synthetic intelligence, we’re in a position to match, educate and activate our quickly rising group of sufferers taking a extra energetic position of their healthcare. This distinctive method continues to efficiently take away the obstacles and biases that traditionally prevented most cancers sufferers from accessing superior therapy choices,” the corporate’s cofounder and CEO Tzvia Bader stated in a press release.
“Trialjectory’s mannequin fosters a high-level of engagement with most cancers sufferers. These trusted relationships, mixed with the strong information and perception we offer pharma, [create] a brand new alternative to place the affected person as a vital stakeholder serving to to rework the trade’s method to patient-centricity. We’re excited to work with Perception Companions as we proceed to develop.”
AllStripes, an analogous platform the place sufferers with uncommon illnesses can entry and submit their medical data for medical trials, introduced it had raised $50 million in Series B financing in August.
There are a selection of well being tech startups that intention to enhance most cancers care. Final month, Reimagine Care scored $25 million for its home-based most cancers administration providers.
Jasper Well being additionally just lately scooped up $25 million in Sequence A funding for its care coordination app that helps customers observe signs, control mediations and chat with social staff.
In August, oncology-focused information science and AI firm ConcertAI introduced it was expanding its partnership with pharma firm Janssen to enhance research design and diversify medical trials.